Clinical Trial Update: Efficacy and Safety of Stapokibart for Primary Cutaneous Amyloidosis [NA]

View source ↗

Summary

Clinical trial update on the efficacy and safety of Stapokibart for primary cutaneous amyloidosis; the study is currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Amyloidosis

Drugs mentioned

• Stapokibart

Snippet

Sponsor: First Affiliated Hospital of Chongqing Medical University | Conditions: Primary Cutaneous Amyloidosis | NA | Status: NOT_YET_RECRUITING